Zevra Therapeutics ZVRA Institutional Ownership

Updated Oct 11, 2026

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) was held by 157 institutional investors that filed 13F reports for the quarter ended June 30, 2026.

• Their combined stake equaled 75.52% of outstanding shares in Q2 2026, up from 69.89% in Q1 2026.
• Total holdings of Zevra Therapeutics shares rose 8.48% from Q1 2026, and the number of holders rose 34.19% from Q2 2025.
• Of these 157 holders, 92 added to their positions, 42 reduced their stakes and 23 left their positions unchanged.
• The aggregate institutional position in Zevra Therapeutics was 44.81Mn shares at the end of Q2 2026, up 3.5Mn from the prior quarter and up 8.95Mn from a year earlier.
• BlackRock, Inc. was the top holder of Zevra Therapeutics as of June 30, 2026, with 5.11Mn shares, or 8.61% of shares outstanding.
• The biggest increases in ZVRA positions during Q2 2026 came from FMR LLC (+1.7Mn shares), Woodline Partners LP (+1.33Mn shares), BlackRock, Inc. (+652.39K shares), D. E. Shaw & Co., Inc. (+460.49K shares) and Dimensional Fund Advisors LP (+404.03K shares).
• Among holders that kept a stake in Zevra Therapeutics, the biggest sellers in Q2 2026 were Nantahala Capital Management, LLC (-724.46K shares), Citadel Advisors LLC (-614.53K shares), Millennium Management LLC (-499.81K shares), Marshall Wace, LLP (-369.67K shares) and UBS Group AG (-277.21K shares).
• Business Quant data shows the 10 biggest positions in Zevra Therapeutics as of Q2 2026 were held by BlackRock, Inc. (5.11Mn shares), FMR LLC (4.92Mn shares), Woodline Partners LP (4.79Mn shares), Vanguard Capital Management LLC (2.64Mn shares), Nantahala Capital Management, LLC (1.8Mn shares), State Street Corp (1.68Mn shares), Geode Capital Management, LLC (1.54Mn shares), D. E. Shaw & Co., Inc. (1.31Mn shares), Qube Research & Technologies Ltd (1.24Mn shares) and Morgan Stanley (1.2Mn shares).